Bristol-Myers (BMY), AstraZeneca (AZN) Report Significant Data from Dapagliflozin Phase 3 in HbA1c Reduction for Type 2 Diabetes Patients

June 11, 2012 7:23 AM EDT Send to a Friend
Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced results from a Phase 3 clinical study that showed ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login